Agenus | AGEN - Sales Revenues


Agenus reported $34.2M in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
AbbVie USD 16.62B 840M Dec/2025
Agenus USD 34.2M 3.97M Dec/2025
Amgen USD 9.9B 340M Dec/2025
AstraZeneca USD 15.5B 313M Dec/2025
Bristol-Myers Squibb USD 12.5B 300M Dec/2025
Celldex Therapeutics USD 121K 769K Dec/2025
CSL USD 8.33B 4.79B Dec/2025
Eli Lilly USD 19.3B 1.7B Dec/2025
Gilead Sciences USD 7.93B 130M Dec/2025
GlaxoSmithKline GBP 8.62B 73M Dec/2025
Glaxosmithkline GBP 11.46B 59.16M Dec/2025
Incyte USD 1.51B 140M Dec/2025
Intrexon USD 717K 511K Jun/2024
J&J USD 24.1B 500M Mar/2026
Jiangsu Hengrui CNY 8.44B 1.01B Dec/2025
Karyopharm Therapeutics USD 34.08M 3.54M Dec/2025
MacroGenics USD 41.23M 31.61M Dec/2025
Merck EUR 5.25B 70M Dec/2025
Merck USD 16.4B 880M Dec/2025
Northwest Biotherapeutics USD 200K 245K Sep/2025
Novartis USD 13.86B 50M Dec/2025
Novavax USD 147.14M 76.69M Dec/2025
Pfizer USD 17.58B 880M Dec/2025
Regeneron Pharmaceuticals USD 3.88B 130M Dec/2025
Rigel Pharmaceuticals USD 55.31M 18.47M Sep/2024
Sangamo BioSciences USD 356K 125K Jun/2024
Veracyte USD 140.6M 8.7M Dec/2025